Abstract: Vernakalant is a new antiarrhythmic agent for the treatment of atrial brillation. While it has proven to be e ective in a large share of patients in clinical studies, its underlying mode of action is not fully understood. In this work, we aim to link experimental data from the subcellular, tissue, and system level using an in-silico approach. A Hill's equation-based drug model was extended to cover the frequency dependence of sodium channel block. Two model variants were investigated: M1 based on subcellular data and M2 based on tissue level data. 6 action potential (AP) markers were evaluated regarding their dose, frequency and substrate dependence. M1 comprising potassium, sodium, and calcium channel block reproduced the reported prolongation of the refractory period. M2 not including the e ects on potassium channels reproduced reported AP morphology changes on the other hand. The experimentally observed increase of ERP accompanied by a shortening of APD was not reproduced. Thus, explanations for the drug-induced changes are provided while none of the models can explain the e ects in their entirety. These results foster the understanding of vernakalant's cellular mode of action and point out relevant gaps in our current knowledge to be addressed in future in-silico and experimental research on this aspiring antiarrhythmic agent.
Introduction
Atrial brillation (AF) is the most common sustained arrhythmia in humans a ecting almost 2% of the popula-tion in the developed world [1] . As the two major strategies ablation therapy and drug therapy fail to succeed in about one third of all patients, AF is still a major challenge motivating the search for new drugs. Current antiarrhythmic agents su er from limited e cacy or severe side-e ects such as provoking life-threatening torsades de pointes arrhythmia in the ventricles. Vernakalant is a new multichannel blocker for pharmacological cardioversion of AF and proved to be superior to both placebo and the existing intravenous agent amiodarone in several clinical studies [1] . Despite its clinical e cacy, the underlying mode of action on atrial myocytes is not understood. One experimental study investigated the e ect on isolated ion channels [2] . Wettwer et al. assessed the e ect on tissue preparations [3] and Dorian et al. [4] studied the effect on atrial and ventricular refractory period in humans. However, these results on di erent integration levels could not be linked until now. In this work, we try to elucidate the complex non-linear e ects of vernakalant on the cellular level by linking the experimental data from the single channel level to tissue level data.
Methods . Electrophysiological model
Cellular electrophysiology was modeled using the Courtemanche-Ramirez-Nattel model of human atrial myocytes [5] in the Control case. To represent chronic AF (cAF) induced remodeling, several conductivities were altered as described before [6] . In brief, I to was reduced by 65%, I K was increased by 100%, I Ks was increased by 100%, I Kur was reduced by 50%, I CaL was reduced by 55%, I Na,Ca was increased by 60%, and the SR leak current was increased by 50%. Furthermore, the cell capacitance was increased by 20%. An implementation of the monodomain model [7] was utilized to simulate excitation propagation in a onedimensional tissue strand of size 20 × 0.1 × 0.1 mm . The domain was discretized by cubic voxels with a side length of 0.1 mm. The monodomain conductivity was set to .
Drug model
Vernakalant reduces the conductance of several atrial ionic currents. We modeled its e ect based on Hill's equation:
with Θ being the degree of channel blockage ranging from 0 to 1, IC being the half maximal inhibitory concentration, D being the free drug concentration, and nH being the Hill coe cient. degrees of block at 10 µM and 30 µM, frequency-speci c IC / nH value pairs were estimated.
Results
The bisection-based tuning of g Na reduction aiming at a replication of experimentally observed dVm /dtmax reduction converged for all substrates, frequencies, and concentrations. The resulting degree of g Na block is shown in Table 2 . The degree of I Na block increased with increasing frequency as can be seen from the frequency-speci c IC and nH values in Table 1 . This e ect is re ected in lower IC values as well as in reduced Hill coe cients. Figure 1 reveals that this resulted in a consistently higher degree of block for higher frequencies within a concentration range of 1 -35 µM. The frequency dependence was less pronounced in the cAF substrate than in Control. The in-silico drug models were used to simulate a train of APs in the tissue strand environment (see Figure 2 ). In the Control substrate, 2:1 block occured at 3 Hz stimulation frequency using the drug model M1. For all other combinations, APs could be induced continuously, although alternans was observed in some of the models. Besides the upstroke velocity, 6 further AP markers were evaluated for the 6 th AP: e ective refractory phase (ERP), AP duration at 90% and 20% repolarization (APD , APD ), AP amplitude (APA), resting membrane potential (RMP), and PLT de ned as the mean potential in the time window between 20% and 30% repolarization. 
However, we did not observe the drug-induced increase of the divergence between ERP and APD (ERP prolongation accompanied by APD shortening) reported particularly for the Control substrate. Model M2 on the other hand covered the APD reduction as well as the increase of PLT whilst not replicating the ERP prolongation. The remaining AP markers were replicated su ciently by both drug models.
Discussion
We showed how vernakalant prolongs the atrial refractory period by blocking the potassium currents I Kr , I Kur , subcellular experimental data but chosen to match experimentally observed AP morphology. This model provides a possible explanation of how APD and PLT are a ected by vernakalant based on the delicate balance of inward and outward currents during the AP plateau and repolarization phase. PLT has to be considered with caution, though, as APD values di er signi cantly for some of the investigated combinations. Our ndings are unlikely to be signi cantly a ected by the choice of the atrial cell model as results using the model by Maleckar et al. [9] were very similar (data not shown). While each of the models provides hypotheses for part of the experimentally observed characteristics, none of the setups is capable of reproducing and explaining the entirety of the observed e ects. This fact reveals a missing piece of the puzzle in our understanding of vernakalant and throws up new questions. Future work might consider more complex drug models describing frequencydependent block directly rather than using several Hill formulations. Another aspect, which might need to be covered in order to explain the experimentally observed increase in the di erence between ERP and APD more comprehensively, is state-dependency.
In conclusion, our results foster the understanding of vernakalant's cellular mode of action and point out relevant gaps in our current knowledge. This study will thus hopefully fuel and direct future in-silico and experimental research on this aspiring antiarrhythmic agent.
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